MDT Stock Recent News

Medtronic said on Monday it will appoint Renault's finance chief Thierry Piéton as its Chief Financial Officer, effective March 3.

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program GALWAY, Ireland , Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the Symplicity™ Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland , Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center.

Medtronic remains an attractive investment due to its diversified revenue streams, robust product pipeline and improving margins. MDT's growth is driven by strong performance in Neuroscience, Cardiovascular, and Diabetes care, with significant international revenue growth and a promising product pipeline. Trading below its historical valuation, MDT offers a compelling opportunity for conservative investors seeking quality at a reasonably low price.

The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.

Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.

Medtronic plc (NYSE:MDT ) 2024 Wells Fargo Healthcare Conference September 4, 2024 11:35 AM ET Company Participants Geoff Martha - Chairman & CEO Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Good afternoon or good morning, and it's about to be good afternoon and welcome to the 2024 Wells Fargo Healthcare Conference. Thank you for helping make this our largest healthcare conference yet.

Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, where the company's business is toughest, and much more.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday.

While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing offered by AI can improve patient outcomes. From more precise diagnosis to pandemic modeling, the large-scale algorithmic models we call AI can help the world of medicine immensely.